- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT07907328
FUS Neuromodulation for Binge Eating Disorder
Early Feasibility Study of Focused Ultrasound (FUS) Neuromodulation in Patients With Binge Eating Disorder
This study is a prospective, single-center, single-arm early feasibility study, to establish safety and tolerability of FUS neuromodulation in patients with Binge Eating Disorder (BED)
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Detaljert beskrivelse
The primary objective is to evaluate the safety, feasibility and tolerability of FUS as an adjunct neuromodulatory treatment for BED
Studietype
Registrering (Antatt)
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiekontakt
- Navn: Jennifer Marton
- Telefonnummer: 304-293-5886
- E-post: jmarton@hsc.wvu.edu
Studer Kontakt Backup
- Navn: Padma Tirumalai
- Telefonnummer: 304-276-0500
- E-post: ptirumalai@hsc.wvu.edu
Studiesteder
-
-
West Virginia
-
Morgantown, West Virginia, Forente stater, 26506
- West Virginia University: Rockefeller Neuroscience Institute
-
Ta kontakt med:
- Study Coordinator
- Telefonnummer: 304-293-0930
- E-post: tldeal@hsc.wvu.edu
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
A candidate will be eligible if they meet all the following criteria:
- Age 18-80 years at time of enrollment.
- Diagnosis of moderate to extreme binge eating disorder (BED) per DSM-5-TR criteria
- Participant is able and willing to give informed consent.
- Participant is willing to cooperate with the study requirements, including compliance with the regimen, completion of all study visits, and study assessments.
- Participants of reproductive potential must have negative pregnancy test and agree to use acceptable forms of contraception.
- Participant able to communicate sensations during the procedure.
A candidate will be excluded if they meet any of the following criteria:
- Unable to undergo MR-imaging or clinically significant MRI findings
- History of any clinically significant neurological disorder.
- Evidence of substance (alcohol or other drug) use disorder during the previous 12 months .
- Past or present diagnosis of psychotic disorder or bipolar disorder
- Currently taking opioid pain medications or positive drug screen for opiates.
- If participants are on medication for the treatment of binge eating disorder or obesity (they must be on a stable dose for at least one month and agree to not begin a medication until after their Week 12 visit.
- Subject has a lifetime history or current symptoms consistent with bulimia nervosa or anorexia nervosa .
- Have a recorded or self-reported change in body weight >11 lbs. within 3 months prior to screening
- Have a prior or planned surgical treatment for obesity (excluding lap-band if removed >6 months prior to screening or liposuction or abdominoplasty if performed >1 year prior to screening)
- Have or plan to have endoscopic and/or device-based therapy for obesity or have had device removal within the last 6 months prior to screening
- History of medically verified suicide attempt within the past year. Clinically significant suicide risk
- Participant who is currently participating in another clinical investigation with an active treatment arm.
- Participant is considered to be a poor surgical or study candidate, which may include, but is not limited to the following: any medical, social, or psychological problem that could complicate the required procedures and evaluations of the study in the judgment of the investigator.
- Participant is pregnant/ lactating or planning to be pregnant.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: N/A
- Intervensjonsmodell: Enkeltgruppeoppdrag
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: FUS Neuromodulation
|
Subjects will undergo a single LIFU of the target brain region |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Occurrence of Treatment Emergent Adverse Events
Tidsramme: baseline compared to 4 and 12 weeks after study procedure
|
All adverse events that are related to FUS procedure will be assessed |
baseline compared to 4 and 12 weeks after study procedure
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Change in Food craving
Tidsramme: Week 4 and 12 comparisons will be made relative to baseline
|
Visual Analog scale |
Week 4 and 12 comparisons will be made relative to baseline
|
|
Change in Eating behavior
Tidsramme: Week 4 and 12 comparisons will be made relative to baseline
|
As measured by self-report binge eating, the Eating Disorder Examination-Interview (EDE-I), |
Week 4 and 12 comparisons will be made relative to baseline
|
|
change in eating Behavior
Tidsramme: Week 4 and 12 comparisons will be made relative to baseline
|
As measured by self-report binge eating Eating Disorder Examination Questionnaire EDE_Q |
Week 4 and 12 comparisons will be made relative to baseline
|
Samarbeidspartnere og etterforskere
Sponsor
Etterforskere
- Hovedetterforsker: Ali Rezai, WVU Rockefeller Neuroscience Institute
Studierekorddatoer
Studer hoveddatoer
Studiestart (Antatt)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- FUS_NMD_BED02
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
produkt produsert i og eksportert fra USA
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .